{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:37:20Z","timestamp":1784039840740,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06310-4","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:13:55Z","timestamp":1743552835000},"page":"2013-2016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory\/relapsed multiple myeloma patient showing poor prognosis"],"prefix":"10.1007","volume":"104","author":[{"given":"Ran","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"5","key":"6310_CR1","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/bjh.19751","volume":"205","author":"C Gr\u00e9goire","year":"2024","unstructured":"Gr\u00e9goire C, Coutinho de Oliveira B, Caimi PF et al (2024) Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice. Br J Haematol 205(5):1699\u20131713. https:\/\/doi.org\/10.1111\/bjh.19751","journal-title":"Br J Haematol"},{"issue":"7","key":"6310_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN (2024) Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 21(7):501\u2013521. https:\/\/doi.org\/10.1038\/s41571-024-00903-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"6310_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jama.2024.1011","volume":"331","author":"M Suran","year":"2024","unstructured":"Suran M (2024) FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers. JAMA 331(10):818\u2013820. https:\/\/doi.org\/10.1001\/jama.2024.1011","journal-title":"JAMA"},{"key":"6310_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A et al (2024) Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine 73:102684. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102684","journal-title":"EClinicalMedicine"},{"issue":"5","key":"6310_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2024) Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143(5):404\u2013416. https:\/\/doi.org\/10.1182\/blood.2023020854","journal-title":"Blood"},{"issue":"10","key":"6310_CR6","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","volume":"8","author":"M Melody","year":"2024","unstructured":"Melody M, Epperla N, Shouse G et al (2024) Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv 8(10):2327\u20132331. https:\/\/doi.org\/10.1182\/bloodadvances.2024012573","journal-title":"Blood Adv"},{"issue":"1","key":"6310_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH et al (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol 17(1):23. https:\/\/doi.org\/10.1186\/s13045-024-01530-z","journal-title":"J Hematol Oncol"},{"issue":"17","key":"6310_CR8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Fowler NH, Dickinson M et al (2024) Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood 143(17):1713\u20131725. https:\/\/doi.org\/10.1182\/blood.2023021567","journal-title":"Blood"},{"issue":"30","key":"6310_CR9","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/jco.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ et al (2024) Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 42(30):3581\u20133592. https:\/\/doi.org\/10.1200\/jco.23.02786","journal-title":"J Clin Oncol"},{"issue":"6","key":"6310_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG et al (2023) Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 41(6):1265\u20131274. https:\/\/doi.org\/10.1200\/jco.22.00842","journal-title":"J Clin Oncol"},{"issue":"11","key":"6310_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med 388(11):1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"issue":"4","key":"6310_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K et al (2023) Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 389(4):335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa2303379","journal-title":"N Engl J Med"},{"issue":"2","key":"6310_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ et al (2023) Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 389(2):148\u2013157. https:\/\/doi.org\/10.1056\/NEJMoa2301665","journal-title":"N Engl J Med"},{"issue":"16","key":"6310_CR14","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1182\/bloodadvances.2021006193","volume":"6","author":"U Jaeger","year":"2022","unstructured":"Jaeger U, Tam CS, Borchmann P et al (2022) Long-term safety for patients with tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 6(16):4816\u20134820. https:\/\/doi.org\/10.1182\/bloodadvances.2021006193","journal-title":"Blood Adv"},{"issue":"20","key":"6310_CR15","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R et al (2024) Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clin Cancer Res 30(20):4690\u20134700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1798","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6310_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/2643-3230.Bcd-21-0177","volume":"3","author":"NY Saini","year":"2022","unstructured":"Saini NY, Swoboda DM, Greenbaum U et al (2022) Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov 3(5):385\u2013393. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0177","journal-title":"Blood Cancer Discov"},{"issue":"13","key":"6310_CR17","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.3390\/cancers15133471","volume":"15","author":"V Vainstein","year":"2023","unstructured":"Vainstein V, Avni B, Grisariu S et al (2023) Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg? Cancers (Basel) 15(13):3471. https:\/\/doi.org\/10.3390\/cancers15133471","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6310_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Xu J, Dai Y et al (2024) Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat Commun 15(1):360. https:\/\/doi.org\/10.1038\/s41467-023-44648-3","journal-title":"Nat Commun"},{"issue":"6","key":"6310_CR19","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J et al (2023) Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. The Lancet Haematology 10(6):e433\u2013e444. https:\/\/doi.org\/10.1016\/S2352-3026(23)00073-X","journal-title":"The Lancet Haematology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06310-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06310-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06310-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:51Z","timestamp":1745575851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06310-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6310"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06310-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare the consent to publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish declaration"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to publish declaration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}